Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Critical Mineral Executive Order Issued by President Donald Trump (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Healthcare Drug Manufacturers - Specialty & Generic
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

Recent & Breaking News (TSXV:VM)

InvestmentPitch Media Video Discusses Voyageur Pharmaceuticals' PEA with NPV of $344 million and 137% IRR for Frances Creek Pharmaceutical Barium Project in BC - Video Available on Investmentpitch.com

Newsfile January 13, 2022

IIROC Trading Resumption - VM

PR Newswire January 11, 2022

Voyageur Pharmaceuticals Announces IRR of 137% and NPV of $344 Million from Preliminary Economic Assessment for the Frances Creek Pharmaceutical Barium Project

TheNewsWire January 11, 2022

IIROC Trading Halt - VM

PR Newswire January 11, 2022

Voyageur Pharmaceuticals Provides Update on PEA Progress & Takes a Major Step Towards Production Start Up

TheNewsWire December 6, 2021

InvestmentPitch Media Video Discusses Voyageur Pharmaceuticals' MOU with Summit Nanotech to Develop Iodine Extraction Technology and Additions to Scientific Advisory Board - Video Available on Investmentpitch.com

Newsfile November 9, 2021

Voyageur Pharmaceuticals & Summit Nanotech Corporation Sign Memorandum of Understanding for a Technology Development Project

TheNewsWire November 8, 2021

Voyageur Pharmaceuticals Ltd., Announces The Completion of a New Scientific Advisory Board With World Class Leading Physicians

TheNewsWire October 18, 2021

Voyageur Pharmaceuticals Ltd., Announces The Creation of a New Scientific Advisory Board With World Class Leading Physicians

TheNewsWire September 14, 2021

Voyageur Pharmaceuticals Ltd. Announces Update To PEA and a Related New Opportunity To Market High Purity USP Barium Sulfate

TheNewsWire August 19, 2021

Voyageur Pharmaceuticals Ltd. Announces Issuance of Stock Options and Deferred Share Units

TheNewsWire August 12, 2021

Voyageur Pharmaceuticals Announces Board of Director Changes and 2nd quarter Financial Results

TheNewsWire July 26, 2021

Voyageur Pharmaceuticals Ltd. Announces Completion of Private Placement

TheNewsWire June 14, 2021

Voyageur Pharmaceuticals Ltd. Announces Closing of Second Tranche of Private Placement

TheNewsWire May 28, 2021

Voyageur Pharmaceuticals (TSXV:VM) receives license for MultiXthick radiographic barium

Trevor Abes  May 18, 2021

Voyageur Pharmaceuticals Ltd. Issuance of 5th Product License for MultiXThick Radiographic Barium Contrast

GlobeNewswire May 18, 2021

Voyageur Pharmaceuticals Ltd. Announces Health Canada Approval and Issuance of 5th Product License for MultiXThick Radiographic Barium Contrast

TheNewsWire May 17, 2021

Voyageur Pharmaceuticals Ltd. Announces Health Canada Approval and Issuance of Product Licenses for MultiXThin Radiographic Barium Contrast

TheNewsWire May 5, 2021

Voyageur Pharmaceuticals Ltd. Issued 4th Health Canada License For Radiographic Barium Contrast Product

GlobeNewswire May 4, 2021

Voyageur Pharmaceuticals Ltd. Announces Increase to Private Placement

TheNewsWire April 23, 2021